S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:VECT

VectivBio (VECT) Stock Price, News & Analysis

$16.85
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$16.85
$16.85
50-Day Range
$16.85
$16.85
52-Week Range
$4.25
$16.98
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
VECT stock logo

About VectivBio Stock (NASDAQ:VECT)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

VECT Stock Price History

VECT Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Only two sleeps left until February 31!
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Ironwood seals the deal on VectivBio merger
Q2 2023 Ironwood Pharmaceuticals Inc Earnings Call
See More Headlines
Receive VECT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VECT
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+48.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$27.34 million
Book Value
$6.27 per share

Miscellaneous

Free Float
N/A
Optionable
No Data
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Luca Santarelli M.D. (Age 53)
    Founder, CEO & Director
  • Ms. Claudia D'Augusta Ph.D. (Age 53)
    Chief Financial Officer
  • Dr. Christian Meyer M.D. (Age 56)
    Ph.D., Chief Operating Officer
  • Dr. Alain Bernard Ph.D. (Age 66)
    Chief Technology Officer
  • Mr. Patrick Malloy
    Sr. VP of Investor Relations & Strategic Communications
  • Mr. Scott Applebaum (Age 56)
    Chief Legal Officer & Corp. Sec.
  • Mr. Michael Steininger
    Sr. VP & Head of HR
  • Mr. Kevin Harris M.B.A. (Age 52)
    Chief Commercial Officer
  • Dr. Sarah Holland Ph.D. (Age 60)
    Chief Bus. Officer
  • Dr. Omar Khwaja M.D. (Age 53)
    Ph.D., Chief Medical Officer

VECT Stock Analysis - Frequently Asked Questions

Should I buy or sell VectivBio stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VECT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VECT, but not buy additional shares or sell existing shares.
View VECT analyst ratings
or view top-rated stocks.

What is VectivBio's stock price target for 2024?

3 brokers have issued 1-year price objectives for VectivBio's shares. Their VECT share price targets range from $25.00 to $25.00. On average, they expect the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 48.4% from the stock's current price.
View analysts price targets for VECT
or view top-rated stocks among Wall Street analysts.

How have VECT shares performed in 2024?

VectivBio's stock was trading at $16.85 at the beginning of the year. Since then, VECT shares have increased by 0.0% and is now trading at $16.85.
View the best growth stocks for 2024 here
.

When is VectivBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 17th 2024.
View our VECT earnings forecast
.

What ETF holds VectivBio's stock?

Range Cancer Therapeutics ETF holds 8,512 shares of VECT stock, representing 1.45% of its portfolio.

When did VectivBio IPO?

VectivBio (VECT) raised $128 million in an IPO on Friday, April 9th 2021. The company issued 7,500,000 shares at a price of $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are VectivBio's major shareholders?

VectivBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Regency Capital Management Inc. DE (0.00%).

How do I buy shares of VectivBio?

Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VECT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners